XWELL Q2 2023 revenue down 40% YoY; net loss improves to $5.7M; CDC renews $15.9M biosurveillance contract

XWELL, Inc.

2023-Q2 EPS reported -$0.13 vs consensus -$1.43 ▲ beat (+90.9%)

Revenue $8.2M vs $13.6M in Q2 2022; XpresSpa revenue up 59% YoY.
Net loss attributable to common shareholders $5.7M, improved from $7.9M loss.
CDC renews biosurveillance program with contract value ~$15.9M; all XpresCheck locations closed.
Appointed Suzanne Scrabis as CFO effective July 10, 2023.
Cash and marketable securities $31.9M; no long-term debt.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

XWELL, Inc. reported financial results for second quarter ended June 30, 2023.

Period: second quarter ended June 30, 2023
Result: reported results

Exact text from the filing

XWELL, Inc., dated August 14, 2023, announcing certain operating results for the fiscal quarter ended June 30, 2023.

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

XWELL, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-091433

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.